Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
VRDN
VRDN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
VRDN News
Viridian Therapeutics Q4 Earnings Report Analysis
Feb 26 2026
seekingalpha
Commodore Capital Fully Exits Viridian Therapeutics Position
Feb 23 2026
Fool
Commodore Capital Exits Entire Position in Viridian Therapeutics
Feb 23 2026
NASDAQ.COM
Biotech Stocks Surge in 2025 with $30.9 Billion M&A Wave
Dec 31 2025
Benzinga
Viridian Therapeutics (VRDN) Secures FDA Priority Review for Veligrotug in Thyroid Eye Disease
Dec 23 2025
NASDAQ.COM
Argenx Suspends Phase 3 Trial for Thyroid Eye Disease, Opening Opportunities for Competitors Like Viridian Therapeutics
Dec 15 2025
Benzinga
Viridian Therapeutics Grants 171,900 Stock Options to New Employees
Dec 05 2025
Newsfilter
Analyst Predicts Viridian's New Thyroid Eye Treatment May Surpass Amgen's Tepezza
Dec 03 2025
Benzinga
Viridian Metals Closes First Tranche of $591,543 Private Placement
Dec 02 2025
Globenewswire
RBC Capital Maintains Positive Outlook on Viridian Therapeutics (VRDN) After Q3 2025 Performance
Nov 17 2025
Yahoo Finance
Viridian Therapeutics Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Nov 07 2025
Newsfilter
RBC Capital Reaffirms Outperform Rating for Viridian Therapeutics and Increases Price Target to $45
Nov 06 2025
Benzinga
Viridian Shares Drop 8.6% Following $251 Million Public Offering
Oct 22 2025
NASDAQ.COM
Viridian Therapeutics Sets Price for $251 Million Public Stock Offering
Oct 22 2025
Newsfilter
Top Analysts Recommend 3 Best Stocks to Purchase Now, 10/21/2025
Oct 21 2025
TipRanks
Viridian Therapeutics Secures Up to $300 Million in Royalty Financing from DRI Healthcare
Oct 20 2025
Newsfilter
Show More News
